| Dr Emily Kathryn Marotta, DPT | |
|
60 Rockingham Rd, Unit 2, Windham, NH 03087-1347 | |
| (603) 890-8541 | |
| (603) 890-8736 |
| Full Name | Dr Emily Kathryn Marotta |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 14 Years |
| Location | 60 Rockingham Rd, Windham, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013236157 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081S0010X | Physical Medicine & Rehabilitation - Sports Medicine | 3545 (New Hampshire) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scaccia Physical Therapy And Sports Conditioning, Llc | 9133282312 | 4 |
| Scaccia Physical Therapy And Sports Conditioning, Llc | 9133282312 | 4 |
News Archive
Publicly insured Americans who undergo lung transplantation for cystic fibrosis fare markedly worse in the long run than both publicly insured patients in the United Kingdom and privately insured Americans, according to the results of a study conducted by researchers from Johns Hopkins in Baltimore and U.K. colleagues working in that nation's government-funded National Health Service.
More health plans are refusing to cover certain brand-name drugs unless drugmakers offer discounts for them, reports The New York Times.
Researchers at the University of Minnesota have identified a newly emerging illness, named staphylococcal purpura fulminans. The disease begins as a respiratory tract infection, which then is infected by Staphylococcus aureus.
Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
The physician who revolutionized screening methods for glaucoma nearly 20 years ago has patented a new device aimed at detecting glaucoma, a leading cause of blindness.
› Verified 5 days ago
| Entity Name | Scaccia Physical Therapy & Sports Conditioning, Llc |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1174796056 PECOS PAC ID: 9133282312 Enrollment ID: O20090309000433 |
News Archive
Publicly insured Americans who undergo lung transplantation for cystic fibrosis fare markedly worse in the long run than both publicly insured patients in the United Kingdom and privately insured Americans, according to the results of a study conducted by researchers from Johns Hopkins in Baltimore and U.K. colleagues working in that nation's government-funded National Health Service.
More health plans are refusing to cover certain brand-name drugs unless drugmakers offer discounts for them, reports The New York Times.
Researchers at the University of Minnesota have identified a newly emerging illness, named staphylococcal purpura fulminans. The disease begins as a respiratory tract infection, which then is infected by Staphylococcus aureus.
Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
The physician who revolutionized screening methods for glaucoma nearly 20 years ago has patented a new device aimed at detecting glaucoma, a leading cause of blindness.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emily Kathryn Marotta, DPT 60 Rockingham Rd, Unit 2, Windham, NH 03087-1347 Ph: (603) 890-8541 | Dr Emily Kathryn Marotta, DPT 60 Rockingham Rd, Unit 2, Windham, NH 03087-1347 Ph: (603) 890-8541 |
News Archive
Publicly insured Americans who undergo lung transplantation for cystic fibrosis fare markedly worse in the long run than both publicly insured patients in the United Kingdom and privately insured Americans, according to the results of a study conducted by researchers from Johns Hopkins in Baltimore and U.K. colleagues working in that nation's government-funded National Health Service.
More health plans are refusing to cover certain brand-name drugs unless drugmakers offer discounts for them, reports The New York Times.
Researchers at the University of Minnesota have identified a newly emerging illness, named staphylococcal purpura fulminans. The disease begins as a respiratory tract infection, which then is infected by Staphylococcus aureus.
Bristol-Myers Squibb Company announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb's investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).
The physician who revolutionized screening methods for glaucoma nearly 20 years ago has patented a new device aimed at detecting glaucoma, a leading cause of blindness.
› Verified 5 days ago
Dr. Sarah Elizabeth Vose, PT, DPT, MS, CIDN Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 25 Indian Rock Rd Ste 3, Windham, NH 03087 Phone: 603-458-7988 Fax: 603-513-2833 |